Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Debt / NOTE 0.599% 8/0
-
Number of holders
-
46
-
Total 13F principal, excl. options
-
487,706,068
-
Principal change
-
+19,902,911
-
Total reported value, excl. options
-
$508,853,510
-
Value change
-
+$21,852,590
-
Number of buys
-
25
-
Number of sells
-
20
-
Price
-
$1.04
Institutional Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 as of Q2 2019
55 filings reported holding 09061GAH4 - BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 as of 30 Jun 2019.
BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 had 46 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $487,706,068 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included ADVENT CAPITAL MANAGEMENT /DE/, Allianz Asset Management GmbH, MACKAY SHIELDS LLC, LAZARD ASSET MANAGEMENT LLC, ZAZOVE ASSOCIATES LLC, SHENKMAN CAPITAL MANAGEMENT INC, SYMPHONY ASSET MANAGEMENT LLC, JPMORGAN CHASE & CO, Polar Capital LLP, and BAKER BROS. ADVISORS LP.
This table shows the top 46 Bond principal holders of the security as of 30 Jun 2019.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.